Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phospholipid metabolism in protozoan parasites encompasses the de novo synthesis, modification, and scavenging of phospholipids, which are crucial for membrane structure, host cell invasion, nutrient uptake, and immune evasion. Enzymes involved in fatty acid synthesis (FASI/FASII), phospholipases, and other lipid-modifying enzymes represent potential drug targets due to their divergence from mammalian counterparts. Targeting these pathways can disrupt membrane integrity, energy production, and replication, ultimately leading to parasite death. The clinical success of miltefosine against Leishmania validates lipid metabolism as a viable therapeutic target. However, redundancy within protozoan lipid metabolism pathways and potential off-target effects pose challenges for drug development.
Inhibition of lipid synthesis pathways, disruption of membrane integrity, interference with energy production
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phospholipid Metabolism in Protozoa.